Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants

Anti-COVID antibody therapeutics have been developed but not widely used due to their high cost and escape of neutralization from the emerging variants. Here, we describe the development of VHH-IgA1.1, a nanobody IgA fusion molecule as an inhalable, affordable and less invasive prophylactic and ther...

Full description

Bibliographic Details
Main Authors: Qi Li, Fiachra Humphries, Roxie C. Girardin, Aaron Wallace, Monir Ejemel, Alla Amcheslavsky, Conor T. McMahon, Zachary A. Schiller, Zepei Ma, John Cruz, Alan P. Dupuis, Anne F. Payne, Arooma Maryam, Nese Kurt Yilmaz, Kathleen A. McDonough, Brian G. Pierce, Celia A. Schiffer, Andrew C. Kruse, Mark S. Klempner, Lisa A. Cavacini, Katherine A. Fitzgerald, Yang Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
biological sciences
microbiology
SARS-CoV-2
VOC
nanobody
IgA
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.995412/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.995412/full

Similar Items